Figure 2.
Clinical events in The African American Study of Kidney Disease and Hypertension trial. Data represent reductions in risk of the composite clinical outcomes (glomerular filtration rate declines of ≥50% from baseline or 25 mL/min per 1.73 m2, end‐stage renal disease, or death). Source: JAMA. 2002;288:2421–2431 23